GLP-1 receptor agonists

EMA launches #HealthNotHype campaign on safe use of GLP-1 medicines

20 June 2025: The European Medicines Agency has launched its first social media campaign with content creators to promote the safe and responsible use of GLP-1 receptor agonists, using the hashtag #HealthNotHype to broaden the reach of its public health messages.

Campaign launch and scope

EMA said the campaign is focused on raising awareness about the safe and responsible use of GLP-1 receptor agonists. These medicines were initially developed to treat type-2 diabetes, and some GLP-1 receptor agonists are now also indicated for weight management in people living with obesity and weight-related health conditions.

EMA launches #HealthNotHype campaign on safe GLP-1 medicine use with content creators

EMA, 2025: The European Medicines Agency has launched its first social media campaign involving content creators, aiming to raise awareness about the safe and responsible use of GLP-1 receptor agonists through the #HealthNotHype initiative.

Campaign launch and scope

The campaign focuses on medicines that were initially developed to treat type-2 diabetes. EMA said that some GLP-1 receptor agonists are now also indicated for weight management in people living with obesity and weight-related health conditions. The agency noted that these medicines are effective for patients, particularly against a backdrop of rising obesity and diabetes rates worldwide.